<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46880">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495922</url>
  </required_header>
  <id_info>
    <org_study_id>GMMG HD6</org_study_id>
    <nct_id>NCT02495922</nct_id>
  </id_info>
  <brief_title>A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma</brief_title>
  <acronym>GMMG-HD6</acronym>
  <official_title>A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Heidelberg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Heidelberg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in
      induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in
      lenalidomide maintenance treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentre, randomised, parallel group, open, phase III clinical trial, for
      patients with confirmed diagnosis of untreated multiple myeloma requiring systemic therapy .

      Investigational Medicinal Products:Elotuzumab, lenalidomide

      Patients are randomized in one of 4 study arms (A1, A2, B1, B2). Patients randomized in arm
      A1 or A2 will receive 4 cycles VRD (Bortezomib (Velcade®), Lenalidomide (Revlimid®),
      Dexamethasone). Patients in arm B1 or B2 will additionally receive the monoclonal antibody
      Elotuzumab in the 4 cycles VRD. After induction therapy patients undergo intensifying
      therapy according to GMMG standard (usually mobilization therapy followed by stem cell
      collection and autologous stem cell transplantation). After intensification a consolidation
      therapy will be performed with two cycles VRD (A1 und B1) or VRD+ Elotuzumab (A2 und B2),
      followed by Lenalidomide maintenance therapy with (arm A2 and B2) or without (arm A1 and B1)
      additional Elotuzumab. Maintenance therapy will be performed for 2 years.

      Primary objective is the determination of the best of four treatment strategies regarding
      progression-free survival (PFS), defined as time from randomisation to progression or death
      from any cause whichever occurs first.

      The duration of the trial for each patients is expected to be 36-39 months (induction and
      intensification treatment: 7-10 months, 3 months rest between intensification and start of
      consolidation, consolidation 2 months, maintenance phase 24 months).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the best of four treatment strategies regarding Progression Free Survival (PFS)</measure>
    <time_frame>time from randomization to progression or death from any cause whichever comes first, censored after two years of maintenance therapy (i.e. approx. after 36 months after randomisation)</time_frame>
    <description>response evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>time from randomisation to time of death from any cause. Patients still being alive at the time of the analysis will be censored at the date last known to be alive. (assessed up to 80 months)</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rates after induction</measure>
    <time_frame>approx. after 3 months (after induction therapy)</time_frame>
    <description>response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rates after consolidation</measure>
    <time_frame>approx. after 9 months (after consolidation therapy)</time_frame>
    <description>response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival after end of trial</measure>
    <time_frame>time from randomisation to progression or death from any cause whichever comes first, censored at the end date of the trial (i.e. assessed up to 80 months)</time_frame>
    <description>response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best response to treatment during the study</measure>
    <time_frame>response assessment after ca. 3 months, 4 months, 7 months, 9 months,11 months, 14 months, and subsequently every 3 months during maintenance treatment, up to 35 months after start of study treatment.</time_frame>
    <description>response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression, censored at end of the trial</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 80 months</time_frame>
    <description>Response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response, censored at end of the trial</measure>
    <time_frame>assessed up to 80 months</time_frame>
    <description>response evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity during induction treatment, consolidation and maintenance treatment with respect to adverse Events of CTCAE grade 3 or higher</measure>
    <time_frame>from first administration of study drug until 40 days after last administration of study drug or any drug of the study treatment or upon start of a new subsequent chemotherapy, whichever occurs first</time_frame>
    <description>toxicity according CTCAE Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment</measure>
    <time_frame>assessed at baseline, after ca. 3 months, 7 months, 9 months, subsequently every 6 months, up to 36 months</time_frame>
    <description>Questionnaires EORTC-QLQC30 and EORTC-QLQMY20</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elotuzumab</intervention_name>
    <description>10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)</description>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B2</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).
8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).
20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).
12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2).</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting all of the following criteria will be considered for admission to
             the trial:

          -  Confirmed diagnosis of untreated multiple myeloma requiring systemic therapy
             (diagnostic criteria (IMWG updated criteria (2014) )

          -  Measurable disease, defined as any quantifiable monoclonal protein value, defined by
             at least one of the following three measurements:

               -  Serum M-protein ≥ 10g/l (for IgA ≥ 5g/l)

               -  Urine light-chain (M-protein) of ≥ 200 mg/24 hours

               -  Serum FLC assay: involved FLC level ≥ 10 mg/dl provided sFLC ratio is abnormal

          -  Age 18 - 70 years inclusive

          -  WHO performance status 0-3 (WHO=3 is allowed only if caused by MM and not by
             co-morbid conditions)

          -  Negative pregnancy test at inclusion (women of childbearing potential)

          -  For all men and women of childbearing potential: patients must be willing and capable
             to use adequate contraception during the complete therapy. Patients must agree on the
             requirements regarding the lenalidomide pregnancy prevention programme described in
             chapter 6.

          -  All patients must

               -  agree to abstain from donating blood while taking lenalidomide and for 28 days
                  following discontinuation of lenalidomide therapy

               -  agree not to share study drug lenalidomide with another person and to return all
                  unused study drug to the investigator or pharmacist

          -  Ability of patient to understand character and individual consequences of the
             clinical trial

          -  Written informed consent (must be available before enrollment in the trial)

        Exclusion Criteria:

          -  Patients presenting with any of the following criteria will not be included in the
             trial:

          -  Patient has known hypersensitivity to any drugs given in the protocol, notably
             bortezomib, lenalidomide, dexamethasone and elotuzumab or to any of the constituent
             compounds (incl. boron and mannitol).

          -  Systemic AL amyloidosis (except for AL amyloidosis of the skin or the bone marrow)

          -  Previous chemotherapy or radiotherapy during the past 5 years except local
             radiotherapy in case of local myeloma progression.

          -  Severe cardiac dysfunction (NYHA classification III-IV)

          -  Significant hepatic dysfunction (serum bilirubin ≥ 1,8mg/dl and/or ASAT and/or ALAT ≥
             2.5 times normal level), unless related to myeloma.

          -  Patients with renal insufficiency requiring hemodialysis

          -  HIV positivity

          -  Patients with active or history of hepatitis B or C

          -  Patients with active, uncontrolled infections

          -  Patients with peripheral neuropathy or neuropathic pain, CTC grade 2 or higher (as
             defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version
             4.0)

          -  Patients with a history of active malignancy during the past 5 years with the
             exception of basal cell carcinoma of the skin or stage 0 cervical carcinoma treated
             with curative intent

          -  Patients with acute diffuse infiltrative pulmonary and/or pericardial disease

          -  Autoimmune hemolytic anemia with positive Coombs test or immune thrombocytopenia

          -  Platelet count &lt; 75 x 109/l, or, dependent on bone marrow infiltration by plasma
             cells, platelet count &lt; 30 x 109/l (patients with platelet count &lt; 75 x 109/l, but &gt;
             30 x 109/l may be eligible if percentage of plasma cells in bone marrow is ≥ 50%),
             (transfusion support within 14 days before the test is not allowed)

          -  Haemoglobin ≤ 8.0 g/dl, unless related to myeloma

          -  Absolute neutrophil count (ANC) &lt; 1.0 x 10^9/l (the use of colony stimulating factors
             within 14 days before the test is not allowed), unless related to myeloma

          -  Pregnancy and lactation

          -  Participation in other clinical trials. This does not include long-term follow-up
             periods without active drug treatment of previous studies during the last 6 months.

        No patients will be allowed to enrol in this trial more than once.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Goldschmidt, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Klinik V, University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GMMG Study Office</last_name>
    <phone>0049-6221-568198</phone>
    <email>studiensekretariat.gmmg@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uta Bertsch, Dr.</last_name>
    <phone>0049-6221-568015</phone>
    <email>uta.bertsch@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Klausmann, Dr.</last_name>
      <email>mk@klausmann.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Krüger, Dr.</last_name>
      <email>sk@klausmann.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologie gGmbH der Klinikum Mittelbaden gGmbH</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roderico Lopez, Dr.</last_name>
      <phone>07221</phone>
      <phone_ext>914115</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Jutta Hagemeyer, Dr. med.</last_name>
      <phone>07221</phone>
      <phone_ext>914115</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schmidt-Hieber, PD Dr.</last_name>
      <phone>030</phone>
      <phone_ext>940112151</phone_ext>
      <email>martin.schmidt-hieber@helios-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Gerecke, Dr.</last_name>
      <email>christian.gerecke@helios-kliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Onkologisches MVZ Berlin Tegel</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Schwenkler</last_name>
      <phone>030-8105890</phone>
      <email>studienzentrale@onkologie-tegel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie)</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Wolfgang Blau, PD Dr.</last_name>
      <phone>030-450-513511</phone>
      <email>igor.blau@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Axel Nogai, Dr.</last_name>
      <email>axel.nogai@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Görner, Dr. med.</last_name>
      <phone>0521-581-3601</phone>
      <email>martin.goerner@klinikumbielefeld.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich Krümpelmann, Dr.</last_name>
      <email>ulrich.kruempelmann@klinikumbielefeld.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Onkologie Bielefeld GbR</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Görner, Dr. med.</last_name>
      <email>martin.goerner@klinikumbielefeld.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Schwerpunktpraxis</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Nückel, Prof. Dr.</last_name>
      <email>holger.nueckel@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Ute Brückner</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik, Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schroers, Prof. Dr. med.</last_name>
      <phone>0234-2993447</phone>
      <email>roland.schroers@rub.de</email>
    </contact>
    <contact_backup>
      <last_name>Lars Petersen, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Mayer, Dr.</last_name>
      <phone>0228</phone>
      <phone_ext>28717232</phone_ext>
      <email>karin.mayer@ukb.uni-bonn.de;</email>
    </contact>
    <contact_backup>
      <last_name>Matthias Zipfel, Dr.</last_name>
      <email>Matthias.zipfel@ukb.uni-bonn.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ZAHO, Zentrum für ambulante Hämatologie und Onkologie</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Verbeek, Prof. Dr.</last_name>
      <phone>0228</phone>
      <phone_ext>4464000</phone_ext>
      <email>wverbeek@zaho-rheinland.de</email>
    </contact>
    <contact_backup>
      <last_name>Hans Vaupel, Dr.</last_name>
      <email>hvaupel@zaho-rheinland.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Onkologie/Hämatologie</name>
      <address>
        <city>Bottrop</city>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Hannig</last_name>
    </contact>
    <contact_backup>
      <last_name>Dirk Pott</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH, Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, PD Dr. med.</last_name>
      <phone>0371-333-43045</phone>
      <email>m.haenel@skc.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Morgner, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Onkologisches Studienzentrum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrit Dingeldein</last_name>
    </contact>
    <contact_backup>
      <last_name>Georgi Kojouharoff, Dr.</last_name>
      <phone>06151-130480</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie</name>
      <address>
        <city>Darmstadt</city>
        <zip>D-64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Bernhard, Prof. Dr.</last_name>
      <phone>06151-107-6651</phone>
      <email>helga.bernhard@mail.klinikum-darmstadt.de</email>
    </contact>
    <contact_backup>
      <last_name>Tu-Anh Dang, Dr.</last_name>
      <email>tu-anh.dang@mail.klinikum-darmstadt.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curd-David Badrakhan, Dr.</last_name>
      <phone>0203</phone>
      <phone_ext>5462442</phone_ext>
      <email>Curd-David.Badrakhan@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Düsseldorf GmbH</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gnatowski</last_name>
      <phone>02361-90427</phone>
      <phone_ext>33</phone_ext>
      <email>Gnatowski@oncologianova.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Düsseldorf GmbH</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40593</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Guenther, Dr.</last_name>
      <phone>0211-997-1225</phone>
      <email>barbara.guenther@sana.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Fenk, Prof. Dr. med.</last_name>
      <phone>0211-811-7760</phone>
      <email>fenk@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Judith Neukirchen, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Ferstl, Dr.</last_name>
      <phone>09131</phone>
      <phone_ext>8543104</phone_ext>
      <email>Barbara.Ferstl@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Mackensen, Prof.</last_name>
      <email>Andreas.Mackensen@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital Klinik f. Hämatologie und Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Staib, PD Dr.</last_name>
      <email>peter.staib@sah-eschweiler.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank Schlegel, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Dürig, Prof. Dr. med.</last_name>
      <phone>0201-72384621</phone>
      <email>jan.duerig@uni-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Karl Richard Maria Noppeney, Dr.</last_name>
      <phone>0201-72384215</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation</name>
      <address>
        <city>Essen</city>
        <zip>D-45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Wattad, Dr.</last_name>
      <phone>0201-4089 2246</phone>
      <email>m.wattad@kliniken-essen-sued.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Reimer, Prof. Dr.</last_name>
      <phone>0201-4089-0</phone>
      <email>p.reimer@kliniken-essen-sued.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centrum für Hämatologie und Onkologie Bethanien</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Kreutz</last_name>
      <phone>069 / 56 00 56</phone>
      <phone_ext>23</phone_ext>
      <email>birgit.kreutz@chop-studien.de</email>
    </contact>
    <contact_backup>
      <last_name>Ilka Kabisch</last_name>
      <phone>069 / 56 00 56</phone>
      <phone_ext>27</phone_ext>
      <email>ilka.kabisch@chop-studien.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilde Birgit</last_name>
      <phone>069-6301</phone>
      <phone_ext>86708</phone_ext>
      <email>Birgit.Wilde@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Bolling, Dr.</last_name>
      <phone>069-95332118</phone>
      <email>claus.bolling@dk.info</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Schmitt/Eulenbuch</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Roland Schmitt, Dr.</last_name>
      <email>h.r.schmitt@telemed.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Medizinische Klinik IV</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Biemer-Mansouri</last_name>
      <phone>06419854</phone>
      <phone_ext>2602</phone_ext>
      <email>gudrun.biemer-mansouri@innere.med.uni-giessen.de</email>
    </contact>
    <contact_backup>
      <last_name>Serife Dasdan</last_name>
      <phone>06419854</phone>
      <phone_ext>2602</phone_ext>
      <email>Serife.Dasdan@innere.med.uni-giessen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Walter Lindemann, Dr.</last_name>
      <phone>02331-129-0</phone>
      <email>w.lindemann@kkh-hagen.de</email>
    </contact>
    <contact_backup>
      <last_name>Cordula Maria Elisabeth Maciejewski</last_name>
      <email>maciejewskic@kkh-hagen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, II - Med. Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timon Hansen, Dr.</last_name>
      <email>t.hansen@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Mascha Binder, Prof. Dr.</last_name>
      <email>m.binder@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg Altona, II. Med. Klinik</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Salwender, Dr.</last_name>
      <phone>040-181881-1212</phone>
      <email>h.salwender@asklepios.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankhaus Hamm gGmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Lange</last_name>
      <phone>02381-9058313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Fuxius, Dr.</last_name>
      <phone>06221</phone>
      <phone_ext>7149921</phone_ext>
      <email>stefanfuxius@gmx.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg, Med. Klinik V</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GMMG Study Office</last_name>
      <email>studiensekretariat.gmmg@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Hartmut Goldschmidt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Heilbronn</city>
        <zip>74072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Dengler, PD Dr.</last_name>
      <phone>07131-79774979</phone>
      <email>dr.dengler@onkologie-heilbronn.de</email>
    </contact>
    <contact_backup>
      <last_name>Piotr Porowski, Dr.</last_name>
      <email>dr.porowski@onkologie-heilbronn.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SLK Kliniken Heilbronn, Med. Klinik III</name>
      <address>
        <city>Heilbronn</city>
        <zip>D-74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, Prof. Dr. med.</last_name>
      <email>uwe.martens@slk-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Lindauer, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Innere Medizin I</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pfreundschuh, Prof. Dr.</last_name>
      <email>michael.pfreundschuh@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Mahlmann, Dr.</last_name>
      <phone>0631</phone>
      <phone_ext>2031872</phone_ext>
      <email>smahlmann@westpfalz-klinikum.de;</email>
    </contact>
    <contact_backup>
      <last_name>Christian Kunz, Dr.</last_name>
      <email>ckunz@westpfalz-klinikum.de;</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Procaccianti, Dr.</last_name>
      <phone>0721</phone>
      <phone_ext>853505</phone_ext>
      <email>procaccianti@onkologie-ka.de</email>
    </contact>
    <contact_backup>
      <last_name>Franz Mosthaf, Dr.</last_name>
      <phone>0721</phone>
      <phone_ext>853505</phone_ext>
      <email>mosthaf@onkologie-ka.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Praxisklinik für Hämatologie und Onkologie</name>
      <address>
        <city>Koblenz</city>
        <zip>D-56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Thomalla, Dr. med.</last_name>
      <phone>0261-30493-0</phone>
      <email>thomalla@onkologie-koblenz.de</email>
    </contact>
    <contact_backup>
      <last_name>Rudolf Weide, Prof. Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln, Klinik I - Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>D-50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Scheid, Prof. Dr.</last_name>
      <phone>0221-478-6296</phone>
      <email>c.scheid@uni-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Holtick, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum, Gemeinschaftspraxis f. Hämatologie u. Onkologie im Caritas KH</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kremers, Dr.</last_name>
      <phone>06881-501-500</phone>
      <email>stephankremers@onkologie-lebach.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Bauer, PD Dr.</last_name>
      <email>stefanbauer@onkologie-lebach.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe GmbH, Hämatologie-Onkologie</name>
      <address>
        <city>Lemgo</city>
        <zip>D-32657</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Hesse</last_name>
      <email>tanja.hesse@klinikum-lippe.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank Hartmann, Prof. Dr.</last_name>
      <phone>05261-26-4123</phone>
      <email>frank.hartmann@klinikum-lippe.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas M. Ulshöfer, Dr.</last_name>
      <phone>07141</phone>
      <phone_ext>2982525</phone_ext>
      <email>mail@onkologie-ludwigsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Klinik A, Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hoffmann, Dr.</last_name>
      <phone>0621</phone>
      <phone_ext>50340702</phone_ext>
      <email>HoffmanM@klilu.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Uppenkamp, Prof. Dr.</last_name>
      <phone>0621</phone>
      <phone_ext>50340702</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktpraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Mainz</city>
        <zip>55122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Papesch, Dr.</last_name>
      <phone>06131</phone>
      <phone_ext>231271</phone_ext>
      <email>e.papesch-onko-praxis@t-online.de</email>
    </contact>
    <contact_backup>
      <last_name>Ute Kreiter, Dr.</last_name>
      <phone>06131</phone>
      <phone_ext>231271</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, III. Med. Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Munder, PD. Dr. med.</last_name>
      <phone>06131-17-5948</phone>
      <email>markus.munder@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Georg Heß, PD Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Klein, PD Dr.</last_name>
      <phone>0621-383-4114</phone>
      <email>stefan.klein@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mannheimer Onkologie Praxis</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Hensel, Prof. Dr. med.</last_name>
      <email>hensel@mannheimer-onkologie-praxis.de</email>
    </contact>
    <contact_backup>
      <last_name>Dieter Schuster, Dr. med.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Neubauer, Prof. Dr.</last_name>
      <email>neubauer@med.uni-marburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Wollmer, Dr.</last_name>
      <email>wollmer@med.uni-marburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mühlenkreiskliniken (AöR) Johannes Wesling Klinikum Minden, Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Joachim Tischler, Dr.</last_name>
      <phone>0571</phone>
      <phone_ext>7904202</phone_ext>
      <email>hans-joachim.tischler@muehlenkreiskliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Kai Wille, Dr.</last_name>
      <phone>0571</phone>
      <phone_ext>79051193</phone_ext>
      <email>kai.wille@muehlenkreiskliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf GmbH, Franziskuskrankenhaus, Med. Klinik I</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>D-41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ullrich Graeven, PD Dr.</last_name>
      <phone>02161-892-2201</phone>
      <email>Ullrich.Graeven@mariahilf.de</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Herfert</last_name>
      <phone>02161-892-2372</phone>
      <email>heidi.herfert@mariahilf.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Steiniger, Dr.</last_name>
      <phone>0208</phone>
      <phone_ext>9704220</phone_ext>
      <email>heike.steiniger@onkologie-oberhausen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internistisch, Onkologische Gemeinschaftspraxis Dres. Balló</name>
      <address>
        <city>Offenbach</city>
        <zip>63065</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Peter Böck, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Zirpel, Dr.</last_name>
      <phone>0441</phone>
      <phone_ext>7705980</phone_ext>
      <email>info@onkopraxis-oldenburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Reschke, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder, Klinik für Onkologie und Hämatologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Heilmeier, Dr.</last_name>
      <phone>0941</phone>
      <phone_ext>36992152</phone_ext>
      <email>bernhard.heilmeier@barmherzige-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Schlenska-Lange, Dr.</last_name>
      <email>anke.schlenska-lange@barmherzige-regensburg.de;</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg, Ermstalklinik, Medizinische Klinik I</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Wacker, Dr.</last_name>
      <phone>07121</phone>
      <phone_ext>2003988</phone_ext>
      <email>wacker_a@klin-rt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH, Innere Medizin III</name>
      <address>
        <city>Schwäbisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Kraft</last_name>
      <phone>0791-753-4018</phone>
      <phone_ext>4486</phone_ext>
      <email>sabine.kraft@dasdiak.de</email>
    </contact>
    <contact_backup>
      <last_name>Samiha Priwitzer</last_name>
      <email>Samiha.priwitzer@dasdiak.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ZAHO-Zentrum für ambulante Hämatologie und Onkologie, Standort Siegburg</name>
      <address>
        <city>Siegburg</city>
        <zip>D-53721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Fronhoffs, Dr.</last_name>
      <email>sfronhoffs@zaho-rheinland.de</email>
    </contact>
    <contact_backup>
      <last_name>Bettina Bürgel</last_name>
      <phone>02241-5954-23</phone>
      <email>studienbuero@zaho-rheinland.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Jung-Stilling-Krankenhaus, Medizinische Klinik</name>
      <address>
        <city>Siegen</city>
        <zip>57074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Klump, Dr.</last_name>
      <phone>0271</phone>
      <phone_ext>33340160</phone_ext>
      <email>martin.klump@diakonie-suedwestfalen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis für Onkologie und Gastroenterologie</name>
      <address>
        <city>Singen</city>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Fietz, Dr.</last_name>
      <phone>07731</phone>
      <phone_ext>7976620</phone_ext>
      <email>fietz@onkologie-bodensee.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich Banhardt, Dr.</last_name>
      <email>banhardt@onkologie-bodensee.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Speyer</name>
      <address>
        <city>Speyer</city>
        <zip>D-67346</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Scheuer, Dr. med.</last_name>
      <email>l.scheuer@onkologie-speyer.de</email>
    </contact>
    <contact_backup>
      <last_name>Judith Franz-Werner, Dr.</last_name>
      <phone>06232-604460</phone>
      <email>onkologie-speyer@t-online.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, Dr.</last_name>
      <phone>0651</phone>
      <phone_ext>9472571</phone_ext>
      <email>mahlberg@mutterhaus.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Heidel, Dr.</last_name>
      <phone>0651</phone>
      <phone_ext>9472571</phone_ext>
      <email>stefan.heidel@mutterhaus.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen, Med. Klinik und Poliklinik, Abt. II</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Weisel, PD Dr.</last_name>
      <phone>07071-29-84321</phone>
      <email>katja.weisel@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Britta Besemer, Dr.</last_name>
      <email>britta.besemer@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum, Klinik für Innere Medizin II</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Heine</last_name>
      <phone>07721</phone>
      <phone_ext>934061</phone_ext>
      <email>kerstin.heine@sbk-vs.de</email>
    </contact>
    <contact_backup>
      <last_name>Birgit Sauer</last_name>
      <phone>07721</phone>
      <phone_ext>934061</phone_ext>
      <email>Birgit.sauer@sbk-vs.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>June 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Heidelberg Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Hartmut Goldschmidt</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
